Limited Number of Passes Available | In-Person Only | $99 Until February 28

(Discount codes not applicable on Exhibit Hall passes. Must be pharma, biotech, regulatory or academia to qualify.)

THURSDAY, APRIL 3 | 8:00 – 9:30 am

AI-POWERED PLATFORMS IN DRUG DISCOVERY:
TACKLING ANTIBIOTIC RESISTANCE AND AGING THERAPEUTICS

PLENARY KEYNOTE PRESENTATION: Deep Learning for Antibiotic Discovery
James J. Collins, PhD, Termeer Professor, Medical Engineering & Science, Massachusetts Institute of Technology
In this presentation, we highlight the Antibiotics-AI Project, which is a multi-disciplinary, innovative research program that is leveraging MIT's strengths in artificial intelligence, bioengineering, and the life sciences to discover and design novel classes of antibiotics. The Antibiotics-AI Project is focused on developing, integrating, and implementing deep learning models and chemogenomic screening approaches: (1) to predict novel antibiotics from expansive chemical libraries with diverse properties, (2) to design de novo novel antibiotics based on learned structural and functional properties of existing and newly discovered antibiotics, and (3) to identify, using explainable deep learning models, the chemical structures and molecular mechanisms underlying the newly discovered and/or designed antibiotics. With these deep learning approaches, we are utilizing multi-scale computation to embrace and harness the complexity of biology and chemistry, so as to discover, design, and develop new classes of antibiotics, up through preclinical studies. Our platform has been designed so that it can be utilized and applied in a rapid fashion to emerging and re-emerging bacterial pathogens, including multidrug-resistant (MDR) bacteria and extensively drug-resistant (XDR) bacteria.

PLENARY KEYNOTE PRESENTATION: Generative AI, Aging Research and Robotics as a Platform for Drug Discovery: From Hype to Clinical Efficacy
Alex Zhavoronkov, PhD, Founder & CEO, Insilico Medicine

FRIDAY, APRIL 4 | 8:00 – 9:45 am

RECOGNIZING EXCELLENCE IN AI AND INNOVATION: THE LONGITUDE PRIZE & TECHNOLOGICAL BREAKTHROUGHS

PLENARY KEYNOTE AWARDS PRESENTATIONS: Innovative Practices Awards: Excellence in Technological Innovation
Allison Proffitt, Editorial Director, Bio-IT World and Clinical Research News
The Innovative Practices Awards recognizes and celebrates technology innovation in the life sciences. Bio-IT World is currently accepting entries for the 2025 Innovative Practices Awards, a competition designed to recognize partnerships and projects pushing our industry forward. Winners will be announced in early-March 2025, recognized during the Friday, April 4 Plenary Keynote Program, and scheduled to give a podium presentation about their project during the conference. For more details about the Awards and to submit an application, visit www.bio-itworldexpo.com/innovativepractices.

PLENARY KEYNOTE PRESENTATION: The Longitude Prize on ALS: A Groundbreaking Global Prize Harnessing the Power of AI to Drive Treatment for ALS

Tris Dyson, Founder and Managing Director, Challenge Works

Jeff Rothstein, MD, PhD, Professor of Neurology and Neuroscience, Director, Brain Science Institute, John Hopkins University

The Longitude Prize series brings together the brightest minds to solve the world's most challenging innovation problems. The Longitude Prize on ALS, launching in June 2025, will bring together computational biologists, neurodegenerative researchers and AI-driven biotech globally to uncover novel therapeutic targets for ALS.

ADVANCING DRUG DISCOVERY AND HEALTHCARE THROUGH DATA-DRIVEN INNOVATION:
FROM GENOMICS TO THERAPEUTICS

PLENARY KEYNOTE PRESENTATION: Scaling Genomic Medicine: Transforming Newborn Screening through Informatics and Innovation
Robert C. Green, MD, MPH, Professor and Director of Genomes2People Research, Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School
The BabySeq Project has pioneered the integration of genomic sequencing into newborn and childhood screening, uncovering unexpected risk variants and transforming healthcare delivery. This keynote explores the groundbreaking progress in genomic medicine, featuring real-world stories of families impacted by these discoveries. Learn about the informatics challenges and innovative solutions required to scale genomic screening for national and global implementation, reshaping the future of precision medicine.

PLENARY KEYNOTE PRESENTATION: Unlocking the Power of Machine Learning and Data-at-Scale to Deliver with Speed the Best Therapeutic Candidates
Justin M. Scheer, PhD, Vice President In Silico Discovery & Head, Molecular Computational Team, Johnson & Johnson Innovative Medicine
The challenges of high costs, lengthy timelines, and significant attrition have prompted our industry to integrate AI/ML into all aspects of the business. This presentation highlights J&J's strategic investments in AI/ML technologies to enhance the drug discovery processes, including molecule design and optimization. By investing in these technologies with a modality agnostic approach, J&J aims to tackle the hardest targets in drug discovery, ultimately increasing the success rate of delivering better molecules faster.

Limited Number of Passes Available | In-Person Only | $99 Until February 28

(Discount codes not applicable on Exhibit Hall passes,  “Discount Codes are not applicable to Exhibit Hall Passes. Must be pharma, biotech, regulatory or academia to qualify.”)